Lv1
20 积分 2024-01-16 加入
Opportunities and limitations of B cell depletion approaches in SLE
7天前
已完结
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
7天前
已完结
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab
7天前
已完结
Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy
18天前
已完结
Efficacy and safety of telitacicept in patients with class III–V lupus nephritis: A real-world retrospective cohort study
2个月前
已完结
In active lupus nephritis, adding obinutuzumab to standard therapy increased complete renal response rates at 76 wk
2个月前
已完结
Comparative Effectiveness Without Head-to-Head Trials
2个月前
已完结
Lupus nephritis
2个月前
已关闭
Lupus Nephritis
2个月前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
3个月前
已完结
皖公网安备34019202002308
